339 related articles for article (PubMed ID: 8837777)
1. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin.
Stefansson S; Lawrence DA
Nature; 1996 Oct; 383(6599):441-3. PubMed ID: 8837777
[TBL] [Abstract][Full Text] [Related]
2. Binding of urokinase to plasminogen activator inhibitor type-1 mediates cell adhesion and spreading.
Planus E; Barlovatz-Meimon G; Rogers RA; Bonavaud S; Ingber DE; Wang N
J Cell Sci; 1997 May; 110 ( Pt 9)():1091-8. PubMed ID: 9175705
[TBL] [Abstract][Full Text] [Related]
3. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation.
Kjøller L; Kanse SM; Kirkegaard T; Rodenburg KW; Rønne E; Goodman SL; Preissner KT; Ossowski L; Andreasen PA
Exp Cell Res; 1997 May; 232(2):420-9. PubMed ID: 9168821
[TBL] [Abstract][Full Text] [Related]
4. Fibrillar collagen regulation of plasminogen activator inhibitor-1 is involved in altered smooth muscle cell migration.
Tanaka S; Koyama H; Ichii T; Shioi A; Hosoi M; Raines EW; Nishizawa Y
Arterioscler Thromb Vasc Biol; 2002 Oct; 22(10):1573-8. PubMed ID: 12377732
[TBL] [Abstract][Full Text] [Related]
5. Plasminogen activator inhibitor type 1 promotes fibrosarcoma cell migration by modifying cellular attachment to vitronectin via alpha(v)beta(5) integrin.
Takahashi T; Suzuki K; Ihara H; Mogami H; Kazui T; Urano T
Semin Thromb Hemost; 2005 Jun; 31(3):356-63. PubMed ID: 16052409
[TBL] [Abstract][Full Text] [Related]
6. Wound-induced migration of MDA-MB-435 and SKOV-3 cancer cells is regulated by plasminogen activator inhibitor-1.
Whitley BR; Church FC
Int J Oncol; 2005 Sep; 27(3):749-57. PubMed ID: 16077925
[TBL] [Abstract][Full Text] [Related]
7. Kinetic analysis of integrin-dependent cell adhesion on vitronectin--the inhibitory potential of plasminogen activator inhibitor-1 and RGD peptides.
Germer M; Kanse SM; Kirkegaard T; Kjøller L; Felding-Habermann B; Goodman S; Preissner KT
Eur J Biochem; 1998 May; 253(3):669-74. PubMed ID: 9654064
[TBL] [Abstract][Full Text] [Related]
8. Distinct encounter complexes of PAI-1 with plasminogen activators and vitronectin revealed by changes in the conformation and dynamics of the reactive center loop.
Qureshi T; Goswami S; McClintock CS; Ramsey MT; Peterson CB
Protein Sci; 2016 Feb; 25(2):499-510. PubMed ID: 26548921
[TBL] [Abstract][Full Text] [Related]
9. The contributions of integrin affinity and integrin-cytoskeletal engagement in endothelial and smooth muscle cell adhesion to vitronectin.
Stefansson S; Su EJ; Ishigami S; Cale JM; Gao Y; Gorlatova N; Lawrence DA
J Biol Chem; 2007 May; 282(21):15679-89. PubMed ID: 17403662
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological Targeting of Plasminogen Activator Inhibitor-1 Decreases Vascular Smooth Muscle Cell Migration and Neointima Formation.
Ji Y; Weng Z; Fish P; Goyal N; Luo M; Myears SP; Strawn TL; Chandrasekar B; Wu J; Fay WP
Arterioscler Thromb Vasc Biol; 2016 Nov; 36(11):2167-2175. PubMed ID: 27659097
[TBL] [Abstract][Full Text] [Related]
11. Effects of plasminogen activator inhibitor-1-specific RNA aptamers on cell adhesion, motility, and tube formation.
Brandal S; Blake CM; Sullenger BA; Fortenberry YM
Nucleic Acid Ther; 2011 Dec; 21(6):373-81. PubMed ID: 22103403
[TBL] [Abstract][Full Text] [Related]
12. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins.
Czekay RP; Aertgeerts K; Curriden SA; Loskutoff DJ
J Cell Biol; 2003 Mar; 160(5):781-91. PubMed ID: 12615913
[TBL] [Abstract][Full Text] [Related]
13. Effect of pharmacologic plasminogen activator inhibitor-1 inhibition on cell motility and tumor angiogenesis.
Leik CE; Su EJ; Nambi P; Crandall DL; Lawrence DA
J Thromb Haemost; 2006 Dec; 4(12):2710-5. PubMed ID: 17010152
[TBL] [Abstract][Full Text] [Related]
14. The urokinase receptor is a major vitronectin-binding protein on endothelial cells.
Kanse SM; Kost C; Wilhelm OG; Andreasen PA; Preissner KT
Exp Cell Res; 1996 May; 224(2):344-53. PubMed ID: 8612711
[TBL] [Abstract][Full Text] [Related]
15. Plasminogen activator inhibitor-1 and vitronectin expression level and stoichiometry regulate vascular smooth muscle cell migration through physiological collagen matrices.
Garg N; Goyal N; Strawn TL; Wu J; Mann KM; Lawrence DA; Fay WP
J Thromb Haemost; 2010 Aug; 8(8):1847-54. PubMed ID: 20492459
[TBL] [Abstract][Full Text] [Related]
16. Plasminogen activator inhibitor-1 impairs alveolar epithelial repair by binding to vitronectin.
Lazar MH; Christensen PJ; Du M; Yu B; Subbotina NM; Hanson KE; Hansen JM; White ES; Simon RH; Sisson TH
Am J Respir Cell Mol Biol; 2004 Dec; 31(6):672-8. PubMed ID: 15308506
[TBL] [Abstract][Full Text] [Related]
17. Reciprocal regulation of urokinase receptor (CD87)-mediated cell adhesion by plasminogen activator inhibitor-1 and protease nexin-1.
Kanse SM; Chavakis T; Al-Fakhri N; Hersemeyer K; Monard D; Preissner KT
J Cell Sci; 2004 Jan; 117(Pt 3):477-85. PubMed ID: 14679304
[TBL] [Abstract][Full Text] [Related]
18. Epitope mapping for four monoclonal antibodies against human plasminogen activator inhibitor type-1: implications for antibody-mediated PAI-1-neutralization and vitronectin-binding.
Wind T; Jensen MA; Andreasen PA
Eur J Biochem; 2001 Feb; 268(4):1095-106. PubMed ID: 11179976
[TBL] [Abstract][Full Text] [Related]
19. Both u-PA inhibition and vitronectin binding by plasminogen activator inhibitor 1 regulate HT1080 fibrosarcoma cell metastasis.
Praus M; Collen D; Gerard RD
Int J Cancer; 2002 Dec; 102(6):584-91. PubMed ID: 12447999
[TBL] [Abstract][Full Text] [Related]
20. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin.
Waltz DA; Natkin LR; Fujita RM; Wei Y; Chapman HA
J Clin Invest; 1997 Jul; 100(1):58-67. PubMed ID: 9202057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]